Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | MMP1 | P03956 | 1/20 | 0.67 |
| ▸ | MMP2 | P08253 | 1/20 | 0.67 |
| ▸ | MMP9 | P14780 | 1/20 | 0.67 |
| ▸ | MMP8 | P22894 | 1/20 | 0.67 |
| ▸ | MMP13 | P45452 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11239362 | 0.89 | MMP2 (0.60) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL18405967 | 0.89 | NPC1 (0.65) | CA1CA2CA12CA9MMP1 | |
| Acedapsone SCHEMBL152710 | 0.85 | PKM (0.85) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL11526389 | 0.83 | TGM2 (0.62) | PTGS2PKMTGM2 | |
| Acedapsone SCHEMBL22518385 | 0.83 | PKM (0.82) | CA1CA2CA12CA9MMP1 | |
| Acedapsone SCHEMBL28716352 | 0.83 | PKM (0.82) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL1102016 | 0.83 | CA1 (0.69) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL8009645 | 0.83 | CA1 (0.69) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL861674 | 0.82 | SMN1; SMN2 (0.84) | CA1CA2CA12CA9POLB | |
| SCHEMBL58191 | 0.82 | CA1 (0.67) | CA1CA2CA12CA9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867211-B1 | METHOD FOR PREPARATION OF MEDETOMIDINE WITH CHLOROACETONE | LONZA AG (CH) | 2015-12-30 | — | — | EP | claimed |
| EP-2847173-B1 | METHOD FOR PREPARATION OF MEDETOMIDINE | LONZA AG (CH) | 2015-12-30 | — | — | EP | claimed |
| CN-103906730-A | Parp inhibitors | HOFFMANN LA ROCHE | 2014-07-02 | — | — | CN | claimed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | claimed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | claimed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | claimed |
| WO-2025090871-A1 | ELECTROPHILIC PURINE COMPOUNDS FOR MODIFICATION OF PROTEINS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-116848100-A | NOTCH inhibitors and uses thereof | 干细胞协同疗法有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116490499-A | Modulators of MYC family protooncogene proteins | 纳罗医疗公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022167867-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| CN-108863850-B | Biaryl compound and preparation method and application thereof | 复旦大学 | 2021-05-18 | — | — | CN | disclosed |
| EP-3795572-A1 | DARUNAVIR PROPIONATE SOLVATE | Laurus Labs Limited (IN) | 2021-03-24 | — | — | EP | disclosed |
| EP-1313725-B1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0049711-B1 | PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES | BAYER AG (DE) | 1984-02-29 | — | — | EP | disclosed |
| EP-0049711-A1 | Process for the production of nitro-amino-benzenes | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | CA1 4761/4885CA2 4175/4885CA12 4720/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CA1 1696/4885CA2 3811/4885CA12 2431/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CA1 3353/4885CA2 3978/4885CA12 4569/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | CA1 4761/4885CA2 4175/4885CA12 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.